Results 11 to 20 of about 27,357 (215)

Evaluating the Impact of Intestinal Bile Salts on Drug Absorption Using PBPK Modeling: Case Studies With Efavirenz, Cinnarizine, and Posaconazole. [PDF]

CPT Pharmacometrics Syst Pharmacol
ABSTRACT A high number of poorly soluble compounds are being developed; thus, understanding the factors that influence their absorption is critical. Intestinal bile salts, which facilitate micelle‐mediated solubilization, are particularly important for drugs with low solubility and are reported to be highly variable.
Al-Amiry Santos LG, Polak S, Yeo KR.
europepmc   +2 more sources

A Phase 1 Dose-Escalation, Food Effect, and Drug-Drug Interaction Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the MALT1 Inhibitor, SGR-1505, in Healthy Volunteers. [PDF]

Clin Pharmacol Drug Dev
Abstract SGR‐1505 is a novel small‐molecule inhibitor of MALT1, a key mediator of NF‐κB signaling implicated in the pathogenesis of B‐cell malignancies. This study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of SGR‐1505 in healthy volunteers. In this four‐part, open‐label study, 73 participants received single or multiple
Gupta VK, Yoo B, Weiss D, Basile FG, Schuck E, Rubino CM, Zhang S, Maxwell SE, Zheng W, Tan JBL, Stenehjem D, Watkins PB, Dugan M, Yin W, Wright DH, Akinsanya K, Lickliter J.   +16 more
europepmc   +2 more sources

Comparative study of posaconazole and voriconazole for primary antifungal prophylaxis in patients with pediatric acute leukemia

Scientific Reports, 2023
Posaconazole and voriconazole are commonly used for preventing invasive fungal disease (IFD), but few studies compared posaconazole with voriconazole for primary antifungal prophylaxis (PAP) in pediatric acute leukemia.
Songji Tu, Kunlong Zhang, Ningling Wang, Jinhua Chu, Linhai Yang, Zhiwei Xie   +5 more
doaj   +1 more source

Gellan gum–based in situ gelling ophthalmic nanosuspension of Posaconazole

Drug Delivery and Translational Research, 2022
The formulation and delivery of highly hydrophobic drugs in an optimized dosage form is challenging to formulation scientists. Posaconazole has shown promising action in case studies against fungal keratitis.
Purva Khare, Manasi M. Chogale, Pratik Kakade, V. Patravale   +3 more
semanticscholar   +1 more source

Acquisition of cross-azole tolerance and aneuploidy in Candida albicans strains evolved to posaconazole

bioRxiv, 2022
A number of in vitro studies have examined the acquisition of drug resistance to the triazole fluconazole, a first-line treatment for many Candida infections. Much less is known about posaconazole, a newer triazole.
Rebekah J. Kukurudz, Madison Chapel, Quinn Wonitowy, A. Bukari, Brooke Sidney, Riley Sierhuis, A. Gerstein   +6 more
semanticscholar   +1 more source

Exploring the Cocrystal Landscape of Posaconazole by Combining High-Throughput Screening Experimentation with Computational Chemistry

Crystal Growth & Design, 2022
The development of multicomponent crystal forms, such as cocrystals, represents a means to enhance the dissolution and absorption properties of poorly water-soluble drug compounds.
Matteo Guidetti, R. Hilfiker, M. Kuentz, A. Bauer-Brandl, F. Blatter   +4 more
semanticscholar   +1 more source

Posaconazole and fluconazole prophylaxis during induction therapy for pediatric acute lymphoblastic leukemia

Journal of Microbiology, Immunology and Infection, 2021
Purpose: To assess and compare the efficacy and safety of posaconazole with fluconazole for the prevention of invasive fungal infections in children who were undergoing induction therapy for acute lymphoblastic leukemia (ALL).
Tian Zhang, Jie Bai, Mingxia Huang, Ruixiao Li, Yang Liu, Ansheng Liu, Jixin Liu   +6 more
doaj   +1 more source

Role of therapeutic drug monitoring in pulmonary infections : use and potential for expanded use of dried blood spot samples [PDF]

, 2015
Respiratory tract infections are among the most common infections in men. We reviewed literature to document their pharmacological treatments, and the extent to which therapeutic drug monitoring (TDM) is needed during treatment.
Akkerman, Onno W, Alffenaar, Jan-Willem C, Bolhuis, Mathieu S, Hofman, Susan, Koster, Remco A, Stove, Christophe, van Assen, Sander   +6 more
core   +13 more sources

4-aminopyridyl-based lead compounds targeting CYP51 prevent spontaneous parasite relapse in a chronic model and improve cardiac pathology in an acute model of Trypanosoma cruzi infection. [PDF]

, 2017
BackgroundChagas disease, caused by the protozoan Trypanosoma cruzi, is the leading cause of heart failure in Latin America. The clinical treatment of Chagas disease is limited to two 60 year-old drugs, nifurtimox and benznidazole, that have variable ...
Calvet, Claudia Magalhaes, Choi, Jun Yong, de Mesquita, Liliane Batista, de Souza Pereira, Mirian Claudia, Hirata, Ken, Lostracco-Johnson, Sharon, McKerrow, James H, Meuser-Batista, Marcelo, Nogueira, Alanderson, Podust, Larissa M, Roush, William R, Silva, Tatiana Araujo, Siqueira-Neto, Jair Lage, Suzuki, Brian, Thomas, Diane   +14 more
core   +12 more sources

Repurposing Lansoprazole and Posaconazole to treat leishmaniasis: Integration of in vitro testing, pharmacological corroboration, and mechanisms of action

Journal of Food and Drug Analysis, 2022
Leishmaniasis remains a serious public health problem in many tropical regions of the world. Among neglected tropical diseases, the mortality rate of leishmaniasis is second only to malaria. All currently approved therapeutics have toxic side effects and
Yash Gupta, Steven C. Goicoechea, J. Romero, Raman Mathur, T. Caulfield, D. Becker, R. Durvasula, P. Kempaiah   +7 more
semanticscholar   +1 more source